Skip to main content
Erschienen in: Journal of Cancer Survivorship 1/2014

01.03.2014

Evaluating long-term patient-centered outcomes following prostate cancer treatment: findings from the Michigan Prostate Cancer Survivor study

verfasst von: May Darwish-Yassine, Manijeh Berenji, Diane Wing, Glenn Copeland, Raymond Y. Demers, Carol Garlinghouse, Angela Fagerlin, Gail E. Newth, Laurel Northouse, Margaret Holmes-Rovner, David Rovner, Jerry Sims, John T. Wei

Erschienen in: Journal of Cancer Survivorship | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Context

Advances in screening and treatment of prostate cancer have dramatically increased the number of survivors in the US population. Yet the effect of screening is controversial, and in some instances may not be beneficial. Previous studies have typically only reported outcomes of treatment and symptoms within a short time frame following treatment. The persistence of such symptoms over time necessitates an improvement of survivor care so that the medical and support needs of these patients are met.

Objective

This study aims to perform a patient-centered survey of prostate cancer survivors in the Michigan Cancer Registry to identify treatment side effect rates, evaluate survivors' access to preventive care services post-prostate cancer treatment, and assess the informational needs of these survivors regarding their prostate cancer.

Design, setting, and patients

Linking case files of the Michigan Cancer Registry with records from the National Death Index, we identified prostate cancer patients diagnosed between 1985 and 2004 and alive on 31 December 2005. Participants were selected using a stratified cross-sectional sampling strategy to ensure adequate inclusion of survivors based upon race and ethnicity, urban versus rural location, and number of years since diagnosis of prostate cancer. A total of 2,499 surveys were completed and returned.

Main outcome measures

(1) Physical symptoms—assessing bowel, sexual, urinary, and vitality symptoms by treatment modality. (2) Access to care—identifying whether diagnostic tests for prostate cancer (prostate-specific antigen (PSA) and digital rectal examination) were performed. Determining whether the survivors had knowledge of the “watchful waiting” paradigm for prostate cancer surveillance. (3) Informational needs—assessing whether the informational needs of patients were addressed by providers. Evaluating the significant predictors associated with seeking information about prostate cancer from any other source. Identifying what factors influenced a person to actively seek out information and what factors guide which primary information source a survivor would use.

Results

Median duration between prostate cancer diagnosis and survey response was 9 years. Of the study population, 80 % was diagnosed at an early stage. Survivors had reported significant problems in the 4 weeks prior to survey. Of the survivors, 88.1 % reported having a PSA test since diagnosis of prostate cancer, with 93 % of them having it done at least once per year. Of the survivors, 82.6 % reported that a healthcare provider gave them information on prostate cancer. Of this 82.6 %, 86.4 % had this information provided by a urologist, 45.4 % by a primary care physician, and 29.2 % by an oncologist. The primary source of information for these survivors was “healthcare provider” (59.2 %).

Conclusion

Persistent symptoms subsequent to prostate cancer treatment suggest a gap in symptom management. Future research should support long-term studies of active surveillance versus active treatment outcomes to understand the feasibility of minimizing the burden of long-term physical symptoms arising from prostate cancer treatment. Clinicians must assess post-treatment distress long after treatment has ended to identify when supportive care is needed. More informational resources should be allocated to prostate cancer survivors to ensure that they are well-educated about their prognosis.

Implications for Cancer Survivors

This study is needed to ensure that the post-treatment symptoms of prostate cancer survivors are properly addressed and managed by healthcare providers over the long term.
Fußnoten
1
In response to the needs of prostate cancer survivors and providers alike, MDCH, in collaboration with MPHI and the Michigan Cancer Consortium Prostate Cancer Action Committee, developed and disseminated a series of 12 fact sheets with guidelines for use by primary care providers who are managing prostate cancer survivors’ ongoing symptoms. The same collaborative partners developed a companion set of 14 symptom management fact sheets in English, Spanish, and Arabic versions for survivors and their families [31].
 
Literatur
1.
Zurück zum Zitat Surveillance, Epidemiology, and End Results (SEER) Program. limited-use data (1973–2006), National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch; released April 2009, based on the November 2007 submission. www.seer.cancer.gov. Accessed 23 Nov 2009. Surveillance, Epidemiology, and End Results (SEER) Program. limited-use data (1973–2006), National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch; released April 2009, based on the November 2007 submission. www.​seer.​cancer.​gov. Accessed 23 Nov 2009.
3.
Zurück zum Zitat Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103(2):117–28.PubMedCentralCrossRefPubMed Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103(2):117–28.PubMedCentralCrossRefPubMed
4.
Zurück zum Zitat Surveillance, Epidemiology, and End Results (SEER) Program. Research data (1973–2008), Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch; released April 2011, based on the November 2010 submission. www.seer.cancer.gov. Accessed 7 June 2011. Surveillance, Epidemiology, and End Results (SEER) Program. Research data (1973–2008), Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch; released April 2011, based on the November 2010 submission. www.​seer.​cancer.​gov. Accessed 7 June 2011.
5.
Zurück zum Zitat Deimling GT, Bowman KF, Sterns S, Wagner LJ, Kahana B. Cancer-related health worries and psychological distress among older adult, long-term cancer survivors. Psychooncology. 2006;15(4):306–20.CrossRefPubMed Deimling GT, Bowman KF, Sterns S, Wagner LJ, Kahana B. Cancer-related health worries and psychological distress among older adult, long-term cancer survivors. Psychooncology. 2006;15(4):306–20.CrossRefPubMed
6.
Zurück zum Zitat Aziz NM, Rowland JH. Trends and advances in cancer survivorship research: challenge and opportunity. Semin Radiat Oncol. 2003;13(3):248–66.CrossRefPubMed Aziz NM, Rowland JH. Trends and advances in cancer survivorship research: challenge and opportunity. Semin Radiat Oncol. 2003;13(3):248–66.CrossRefPubMed
7.
Zurück zum Zitat Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst. 2004;96(18):1358–67.CrossRefPubMed Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst. 2004;96(18):1358–67.CrossRefPubMed
8.
Zurück zum Zitat Shrader-Bogen CL, Kjellberg JL, McPherson CP, Murray CL. Quality of life and treatment outcomes: prostate carcinoma patients' perspectives after prostatectomy or radiation therapy. Cancer. 1997;79(10):1977–86.CrossRefPubMed Shrader-Bogen CL, Kjellberg JL, McPherson CP, Murray CL. Quality of life and treatment outcomes: prostate carcinoma patients' perspectives after prostatectomy or radiation therapy. Cancer. 1997;79(10):1977–86.CrossRefPubMed
9.
Zurück zum Zitat Litwin MS. Health-related quality of life after treatment for localized prostate cancer. Cancer. 1995;75 Suppl 7:2000–3.CrossRef Litwin MS. Health-related quality of life after treatment for localized prostate cancer. Cancer. 1995;75 Suppl 7:2000–3.CrossRef
10.
Zurück zum Zitat Litwin MS, Hays RD, Fink A, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA. 1995;273(2):129–35.CrossRefPubMed Litwin MS, Hays RD, Fink A, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA. 1995;273(2):129–35.CrossRefPubMed
11.
Zurück zum Zitat Miller DC, Sanda MG, Dunn RL, Montie JE, Pimentel H, Sandler HM, et al. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol. 2005;23(12):2772–80.CrossRefPubMed Miller DC, Sanda MG, Dunn RL, Montie JE, Pimentel H, Sandler HM, et al. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol. 2005;23(12):2772–80.CrossRefPubMed
12.
Zurück zum Zitat Dobs A, Darkes MJM. Incidence and management of gynecomastia in men treated for prostate cancer. J Urol. 2005;174(5):1737–42.CrossRefPubMed Dobs A, Darkes MJM. Incidence and management of gynecomastia in men treated for prostate cancer. J Urol. 2005;174(5):1737–42.CrossRefPubMed
13.
Zurück zum Zitat Potosky AL, Knopf K, Clegg LX, Albertsen PC, Stanford JL, Hamilton AS, et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the prostate cancer outcomes study. J Clin Oncol. 2001;19(17):3750–7.PubMed Potosky AL, Knopf K, Clegg LX, Albertsen PC, Stanford JL, Hamilton AS, et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the prostate cancer outcomes study. J Clin Oncol. 2001;19(17):3750–7.PubMed
14.
Zurück zum Zitat Berruti A, Dogliotti L, Terrone C, Cerutti S, Isaia G, Tarabuzzi R, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol. 2002;167(6):2361–7.CrossRefPubMed Berruti A, Dogliotti L, Terrone C, Cerutti S, Isaia G, Tarabuzzi R, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol. 2002;167(6):2361–7.CrossRefPubMed
15.
Zurück zum Zitat Boxer RS, Kenny AM, Dowsett R, Taxel P. The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancer. The Aging Male. 2005;8(3–4):207–12.CrossRefPubMed Boxer RS, Kenny AM, Dowsett R, Taxel P. The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancer. The Aging Male. 2005;8(3–4):207–12.CrossRefPubMed
16.
Zurück zum Zitat Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001;86(9):4261–7.CrossRefPubMed Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001;86(9):4261–7.CrossRefPubMed
17.
Zurück zum Zitat Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy or prostate cancer. J Urol. 2000;163(1):181–6.CrossRefPubMed Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy or prostate cancer. J Urol. 2000;163(1):181–6.CrossRefPubMed
18.
Zurück zum Zitat Higano C, Shields A, Wood N, Brown J, Tangen C. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology. 2004;64(6):1182–6.CrossRefPubMed Higano C, Shields A, Wood N, Brown J, Tangen C. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology. 2004;64(6):1182–6.CrossRefPubMed
19.
Zurück zum Zitat Shahinian VB, Kuo Y-F, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154–64.CrossRefPubMed Shahinian VB, Kuo Y-F, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154–64.CrossRefPubMed
20.
Zurück zum Zitat Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24(24):3979–83.CrossRefPubMed Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24(24):3979–83.CrossRefPubMed
21.
Zurück zum Zitat Muller M, Grobbee DE, den Tonkelaar I, Lamberts SW, van der Schouw YT. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab. 2005;90(5):2618–23.CrossRefPubMed Muller M, Grobbee DE, den Tonkelaar I, Lamberts SW, van der Schouw YT. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab. 2005;90(5):2618–23.CrossRefPubMed
22.
Zurück zum Zitat Dockey F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond). 2003;104(2):195–201.CrossRef Dockey F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond). 2003;104(2):195–201.CrossRef
23.
Zurück zum Zitat Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448–56.CrossRefPubMed Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448–56.CrossRefPubMed
24.
Zurück zum Zitat Leaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen TP, Valkonen VP, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004;27(5):1036–41.CrossRef Leaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen TP, Valkonen VP, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004;27(5):1036–41.CrossRef
25.
Zurück zum Zitat Satariano WA, Ragland KE, Van Den Eeden SK. Cause of death in men diagnosed with prostate carcinoma. Cancer. 1998;83(6):1180–8.CrossRefPubMed Satariano WA, Ragland KE, Van Den Eeden SK. Cause of death in men diagnosed with prostate carcinoma. Cancer. 1998;83(6):1180–8.CrossRefPubMed
26.
Zurück zum Zitat Smith MR, McGovern FJ, Fallon MA, Schoenfeld D, Kantoff PW, Finkelstein JS. Low bone mineral density in hormone-naïve men with prostate carcinoma. Cancer. 2001;91(12):2238–45.CrossRefPubMed Smith MR, McGovern FJ, Fallon MA, Schoenfeld D, Kantoff PW, Finkelstein JS. Low bone mineral density in hormone-naïve men with prostate carcinoma. Cancer. 2001;91(12):2238–45.CrossRefPubMed
27.
Zurück zum Zitat Poon SA, Silberstein JL, Savage C, Maschino AC, Lowrance WT, Sandhu JS. Surgical practice patterns for male urinary incontinence: analysis of case logs from certifying American urologists. J Urol. 2012;188(1):205–10.PubMedCentralCrossRefPubMed Poon SA, Silberstein JL, Savage C, Maschino AC, Lowrance WT, Sandhu JS. Surgical practice patterns for male urinary incontinence: analysis of case logs from certifying American urologists. J Urol. 2012;188(1):205–10.PubMedCentralCrossRefPubMed
28.
Zurück zum Zitat Faucheron JL, Chodez M, Boillot B. Neuromodulation for fecal and urinary incontinence: functional results in 57 consecutive patients from a single institution. Dis Colon Rectum. 2012;55(12):1278–83.CrossRefPubMed Faucheron JL, Chodez M, Boillot B. Neuromodulation for fecal and urinary incontinence: functional results in 57 consecutive patients from a single institution. Dis Colon Rectum. 2012;55(12):1278–83.CrossRefPubMed
29.
Zurück zum Zitat Chung E, Brock G. Sexual rehabilitation and cancer survivorship: a state of art review of current literature and management strategies in male sexual dysfunction among prostate cancer survivors. J Sex Med. 2013;10 Suppl 1:102–11.CrossRefPubMed Chung E, Brock G. Sexual rehabilitation and cancer survivorship: a state of art review of current literature and management strategies in male sexual dysfunction among prostate cancer survivors. J Sex Med. 2013;10 Suppl 1:102–11.CrossRefPubMed
30.
Zurück zum Zitat Skolarus TA, Zhang Y, Miller DC, Wei JT, Hollenbeck BK. The economic burden of prostate cancer survivorship. J Urol. 2010;184(2):532–8.CrossRefPubMed Skolarus TA, Zhang Y, Miller DC, Wei JT, Hollenbeck BK. The economic burden of prostate cancer survivorship. J Urol. 2010;184(2):532–8.CrossRefPubMed
31.
Zurück zum Zitat Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56(6):899–905.CrossRefPubMed Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56(6):899–905.CrossRefPubMed
32.
Zurück zum Zitat Grunkemeier MN, Vollmer RT. Predicting prostate biopsy results: the importance of PSA, age, and race. Am J Clin Pathol. 2006;126(1):110–2.CrossRefPubMed Grunkemeier MN, Vollmer RT. Predicting prostate biopsy results: the importance of PSA, age, and race. Am J Clin Pathol. 2006;126(1):110–2.CrossRefPubMed
34.
Zurück zum Zitat Bober SL, Recklitis CJ, Campbell EG, Park ER, Kutner JS, Najita JS, et al. Caring for cancer survivors: a survey of primary care physicians. Cancer. 2009;115 Suppl 18:4409–18.CrossRefPubMed Bober SL, Recklitis CJ, Campbell EG, Park ER, Kutner JS, Najita JS, et al. Caring for cancer survivors: a survey of primary care physicians. Cancer. 2009;115 Suppl 18:4409–18.CrossRefPubMed
35.
Zurück zum Zitat Skolarus TA, Holmes-Rovner M, Northouse LL, Fagerlin A, Garlinghouse C, Demers RY, et al. Primary care perspectives on prostate cancer survivorship: implications for improving quality of care. Urol Oncol. 2013;31(6):727–32.PubMedCentralCrossRefPubMed Skolarus TA, Holmes-Rovner M, Northouse LL, Fagerlin A, Garlinghouse C, Demers RY, et al. Primary care perspectives on prostate cancer survivorship: implications for improving quality of care. Urol Oncol. 2013;31(6):727–32.PubMedCentralCrossRefPubMed
36.
Zurück zum Zitat Wei JT, Dunn RL, Sandler HM, McLaughlin PW, Montie JE, Litwin MS, et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol. 2002;20(2):557–66.CrossRefPubMed Wei JT, Dunn RL, Sandler HM, McLaughlin PW, Montie JE, Litwin MS, et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol. 2002;20(2):557–66.CrossRefPubMed
37.
Zurück zum Zitat Smith T, Stein KD, Mehta CC, Kaw C, Kepner JL, Buskirk T, et al. The rationale, design, and implementation of the American Cancer Society's studies of cancer survivors. Cancer. 2007;109(1):1–12.CrossRefPubMed Smith T, Stein KD, Mehta CC, Kaw C, Kepner JL, Buskirk T, et al. The rationale, design, and implementation of the American Cancer Society's studies of cancer survivors. Cancer. 2007;109(1):1–12.CrossRefPubMed
Metadaten
Titel
Evaluating long-term patient-centered outcomes following prostate cancer treatment: findings from the Michigan Prostate Cancer Survivor study
verfasst von
May Darwish-Yassine
Manijeh Berenji
Diane Wing
Glenn Copeland
Raymond Y. Demers
Carol Garlinghouse
Angela Fagerlin
Gail E. Newth
Laurel Northouse
Margaret Holmes-Rovner
David Rovner
Jerry Sims
John T. Wei
Publikationsdatum
01.03.2014
Verlag
Springer US
Erschienen in
Journal of Cancer Survivorship / Ausgabe 1/2014
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-013-0312-8

Weitere Artikel der Ausgabe 1/2014

Journal of Cancer Survivorship 1/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.